Insider Sell: CFO Michael Brophy Sells 2,292 Shares of Natera Inc (NTRA)
Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), executed a sale of 2,292 shares in the company on December 29, 2023, according to a recent SEC Filing. Natera Inc is a diagnostics company specializing in the field of genetic testing. The company's offerings include non-invasive prenatal tests, carrier screening tests, and cancer screening tests, which are designed to provide early and accurate information for patients and healthcare providers.
Over the past year, the insider has sold a total of 133,905 shares and has not made any purchases of the company's stock.
The insider transaction history for Natera Inc indicates a pattern of insider sales, with 58 insider sells recorded over the past year and no insider buys during the same period.
On the date of the insider's recent transaction, shares of Natera Inc were trading at $62.69, giving the company a market capitalization of $7.526 billion.
The stock's price-to-GF-Value ratio stands at 1.05, with a GuruFocus Value of $59.83, indicating that Natera Inc is Fairly Valued based on its GF Value.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, an adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
